FDA — authorised 9 October 2012
- Application: ANDA203690
- Marketing authorisation holder: PPI-DAC
- Status: supplemented
FDA authorised Nicotine Mini on 9 October 2012 · 41 US adverse-event reports
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Yes. FDA authorised it on 9 October 2012; FDA authorised it on 7 February 2019; FDA authorised it on 31 October 2019.
PPI-DAC holds the US marketing authorisation.